Tracker › Companies › enGene Therapeutics Inc.
6 No sign of it. We found no public evidence tying enGene Therapeutics Inc.'s cuts to AI.
Every tracked 2026 layoff at enGene Therapeutics Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 6/100 (Minimal) · 80% interval 5–7 · evidence grade D · US · Pharma / Chemicals
Stated reason: On June 15, 2026, the Company announced the implementation of a plan to reduce its workforce by approximately 50% to streamline operations and preserve cash. The Company’s board of directors (the “Board”) approved this strategic restructuring, effective June 14, 2026, in order to preserve shareholder capital as the Company awaits additional durability data and meetings with the Food and Drug Administration (“FDA”) in…
Why 6: Cost-cutting / efficiency · Drivers: industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.811, industry exposure 0.712, AI investment 0.0, contrary evidence 0.0 · named roles: Bookkeeping, Accounting, and Auditing Clerks, Computer and Information Systems Managers, General and Operations Managers, Loan Interviewers and Clerks, Office C
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 4,500 workers
Health Care & Pharma · 718 workers
Health Care & Pharma · 628 workers
Health Care & Pharma · 278 workers
Health Care & Pharma · 145 workers
Health Care & Pharma · 130 workers
